Drug updated on 4/16/2024
| Dosage Form | Tablet (oral; 100 mg, 150 mg, 200 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Summary
- Momelotinib (Ojjaara) is recommended for the treatment of intermediate or high-risk myelofibrosis, including primary and secondary forms, in adults with anemia. It has shown comparable efficacy to other Janus kinase inhibitors such as ruxolitinib and fedratinib in reducing spleen volume and symptom scores.
- The information was derived from a systematic review/meta-analysis that included seven studies within the network meta-analysis, encompassing 1953 patients randomly assigned to receive one of four JAK inhibitors or a control.
- In terms of safety, momelotinib exhibits less toxicity on erythrocytes compared to other JAK inhibitors, making it particularly suitable for patients suffering from myelofibrosis-related anemia, potentially offering them a better quality of life than alternative treatments.
- Although no explicit subgroup analyses were provided based on population types like age, gender, or race; momelotinib's distinct advantage in managing anemia suggests specific benefits for subgroups within the myelofibrosis patient population who are dealing with this condition.
- Momelotinib appears to be a strong candidate for first-line therapy, similar to ruxolitinib and fedratinib. There's also an indication that pacritinib might be effective as second-line therapy after exposure to ruxolitinib, providing strategic insight into how momelotinib could fit into broader treatment regimens.
- Overall, considering its comparable efficacy with existing FDA-approved treatments along with a favorable safety profile, especially regarding the positive impact on anemia, Ojjaara (momelotinib) may be preferentially considered for patients suffering from myelofibrosis-related anemia, thereby improving their quality of life.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ojjaara (momelotinib) Prescribing Information. | 2023 | GlaxoSmithKline LLC., Philadelphia, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. | 2021 | Blood Cancer Journal |